gatifloxacin has been researched along with Helicobacter Infections in 8 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No significant adverse effects were reported." | 2.72 | Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. ( Abdul-Baki, H; Aoun, E; Araj, GF; Chaar, HF; Kanj, SS; Sharara, AI, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Shao, Y | 1 |
| Lin, Y | 1 |
| Wang, B | 1 |
| Miao, M | 1 |
| Ye, G | 1 |
| Nishizawa, T | 2 |
| Suzuki, H | 2 |
| Nakagawa, I | 1 |
| Iwasaki, E | 2 |
| Masaoka, T | 2 |
| Hibi, T | 2 |
| Hori, K | 1 |
| Suguro, M | 1 |
| Koizuka, H | 1 |
| Sakagami, T | 1 |
| Tomita, T | 1 |
| Kosaka, T | 1 |
| Fukuda, Y | 1 |
| Sharara, AI | 2 |
| Chaar, HF | 2 |
| Racoubian, E | 1 |
| Moukhachen, O | 1 |
| Barada, KA | 1 |
| Mourad, FH | 1 |
| Araj, GF | 2 |
| Watanabe, K | 1 |
| Aoun, E | 1 |
| Abdul-Baki, H | 1 |
| Kanj, SS | 1 |
| Graham, DY | 1 |
| Abudayyeh, S | 1 |
| El-Zimaity, HM | 1 |
| Hoffman, J | 1 |
| Reddy, R | 1 |
| Opekun, AR | 1 |
| Umezawa, A | 1 |
| Muraoka, H | 1 |
| Kobayashi, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori[NCT01573975] | Phase 4 | 345 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for gatifloxacin and Helicobacter Infections
| Article | Year |
|---|---|
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; D | 2008 |
Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Protei | 2006 |
5 other studies available for gatifloxacin and Helicobacter Infections
| Article | Year |
|---|---|
Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Resistance, Bacterial; Fosfomy | 2022 |
Disappearance of rectal mucosa-associated lymphoid tissue lymphoma following antibiotic therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Fluoroquinolones; Gastritis; Gatifloxacin; H | 2004 |
[Evaluation of gatifloxacin-based triple therapy for refractory H. pylori].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Evaluation; Drug Therapy, Combination | 2005 |
Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Infective Agents; Clinical Protocols; Drug Administration Schedule; Drug Therapy, | 2006 |
Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.
Topics: Adult; Aged; Alleles; Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroq | 2007 |